<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03502161</url>
  </required_header>
  <id_info>
    <org_study_id>C16-CMV-001</org_study_id>
    <nct_id>NCT03502161</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of the QuantiFERON CMV Assay</brief_title>
  <official_title>Clinical Evaluation of the QuantiFERON CMV Assay</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>QIAGEN Gaithersburg, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>QIAGEN Gaithersburg, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Validate the use of the device in the clinical setting for assessing the risk of CMV&#xD;
      Infection in SOT recipients after the completion of antiviral prophylaxis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Business decision.&#xD;
  </why_stopped>
  <start_date type="Actual">November 15, 2018</start_date>
  <completion_date type="Actual">June 30, 2020</completion_date>
  <primary_completion_date type="Actual">May 15, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in time to CMV Infection between sub-groups of QF-CMV assay classifications.</measure>
    <time_frame>At time of prophylaxis termination, +1 month from termination, +2 months from termination</time_frame>
    <description>Measurement of QF-CMV result</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">8</enrollment>
  <condition>CMV</condition>
  <arm_group>
    <arm_group_label>All subjects</arm_group_label>
    <description>Those receiving a SOT and coming off either 3 months or 6 months of antiviral prophylaxis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>QuantiFERON CMV Assay</intervention_name>
    <description>Assay to measure cell-mediated immune function using QuantiFERON CMV assay.</description>
    <arm_group_label>All subjects</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Residual Plasma&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        CMV D+/R- SOT recipients older than 18 that are receiving 3-6 months of antiviral&#xD;
        prophylaxis and can provide Informed Consent.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult CMV D+/R- liver, kidney, heart, pancreas, lung, intestinal, or combined&#xD;
             transplant recipients that are 18 years of age or older.&#xD;
&#xD;
          -  Scheduled to receive between 3 to 6 months of antiviral prophylaxis&#xD;
&#xD;
          -  Provide Informed Consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects less than 18 years old&#xD;
&#xD;
          -  Scheduled to receive longer than 6 months or shorter than 3 months of prophylaxis&#xD;
&#xD;
          -  Unable to provide Informed Consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Tolkoff-Rubin N, Rubin R. The impact of cytomegalovirus infection on graft function and patient outcome. Graft 1999; 2:S101-3.</citation>
  </reference>
  <reference>
    <citation>Singh N. Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients. Clin Infect Dis. 2001 Mar 1;32(5):742-51. Epub 2001 Feb 20. Review.</citation>
    <PMID>11229841</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>April 4, 2018</study_first_submitted>
  <study_first_submitted_qc>April 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2018</study_first_posted>
  <last_update_submitted>September 14, 2020</last_update_submitted>
  <last_update_submitted_qc>September 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

